Abstract:The pathophysiology of sepsis alters drug pharmacokinetics, resulting in inadequate drug exposure and target-site concentration. Suboptimal exposure leads to treatment failure and the development of antimicrobial resistance. Therefore, we seek to optimize antimicrobial therapy in sepsis by selecting the right drug and the correct dosage. A prerequisite for achieving this goal is characterization and understanding of the mechanisms of pharmacokinetic alterations. However, most infections take place not in blood but in different body compartments. Since tissue pharmacokinetic assessment is not feasible in daily practice, we need to tailor antibiotic treatment according to the specific patient's pathophysiological processes. The complex pathophysiology of sepsis and the ineffectiveness of current targeted therapies suggest that treatments guided by biomarkers predicting target-site concentration could provide a new therapeutic strategy. Inflammation, endothelial and coagulation activation markers, and blood flow parameters might be indicators of impaired tissue distribution. Moreover, hepatic and renal dysfunction biomarkers can predict not only drug metabolism and clearance but also drug distribution. Identification of the right biomarkers can direct drug dosing and provide timely feedback on its effectiveness. Therefore, this might decrease antibiotic resistance and the mortality of critically ill patients. This article fills the literature gap by characterizing patient biomarkers that might be used to predict unbound plasma-to-tissue drug distribution in critically ill patients. Although all biomarkers must be clinically evaluated with the ultimate goal of combining them in a clinically feasible scoring system, we support the concept that the appropriate biomarkers could be used to direct targeted antibiotic dosing. ADAMTS-13 a disintegrin-like and metalloprotease with thrombospondin type 1 motif no. 13, ALAT alanine amino transferase, APACHE IV Acute Physiology and Chronic Health Evaluation-IV, aPPT activated partial thromboplastin time, ASAT aspartate amino transferase, AT antithrombin, Ca-V-O2 oxygen content difference, arterial-venous, CRP C-reactive protein, ELAM endothelial leukocyte adhesion molecule, ICAM intercellular adhesion molecule, IL interleukin, INR international normalized ratio, LBP lipopolysaccharide-binding protein, MCP monocyte chemoattractant protein, mHLA monocytic human leukocyte antigen, MIF migration inhibitory factor, MIP macrophage inflammatory protein, PAI plasminogen activator inhibitor, PCO2 partial pressure of carbon dioxide, PT prothrombin time, RRT renal replacement therapy, SAPSS III Simplified Acute Physiology Score-III, sO2 oxygen saturation, SOFA Sequential [Sepsis-related] Organ Failure Assessment, sTREM soluble triggering receptor expressed on myeloid cells 1, TLR toll-like receptor, TNF tumor necrosis factor, VCAM vascular cell adhesion molecule, VEGF vascular endothelial growth factor, vWf von Willebrand factor.

Metabolite X is a novel biomarker for sepsis diagnosis and treatment

Deficiency of the Novel High Mobility Group Protein HMGXB4 Protects Against Systemic Inflammation-Induced Endotoxemia in Mice.

Serum metabolite profiling reveals metabolic characteristics of sepsis patients using LC/MS-based metabolic profiles: a cross-sectional study

Landscape of Metabolic Fingerprinting for Diagnosis and Risk Stratification of Sepsis

Discrimination of Sepsis Stage Metabolic Profiles with an LC/MS-MS-based Metabolomics Approach.

Sphingosine 1-Phosphate Receptor-3 Contributes to Host Defense Against Polymicrobial Sepsis Via Modulating Macrophage Chemotaxis (CAM4P.161)

Identification Of Novel Biomarkers For Sepsis Prognosis Via Urinary Proteomic Analysis Using Itraq Labeling And 2d-Lc-Ms/Ms

Association Between Changes in Plasma Metabolism and Clinical Outcomes of Sepsis.

Integrative analysis of metabolomics and transcriptomics to uncover biomarkers in sepsis

Dissecting the mediating role of inflammatory factors in the interaction between metabolites and sepsis: insights from bidirectional Mendelian randomization

Lipidomic profile and candidate biomarkers in septic patients

Analysis of metabolic disturbances attributable to sepsis-induced myocardial dysfunction using metabolomics and transcriptomics techniques

Integrative single-cell RNA sequencing and metabolomics decipher the imbalanced lipid-metabolism in maladaptive immune responses during sepsis

Prognostic biomarkers for sepsis mortality based on the literature and LC-MS-based metabolomics of sepsis patients.

Exploring the circulating metabolome of sepsis: metabolomic and lipidomic profiles sampled in the ambulance

Dynamic changes of serum metabolite profiling in septic mice based on high performance liquid chromatography of quadrupole time of flight mass spectrometry analysis

Serum mitochondrial-encoded NADH dehydrogenase 6 and Annexin A1 as novel biomarkers for mortality prediction in critically ill patients with sepsis

Biomarkers Predicting Tissue Pharmacokinetics of Antimicrobials in Sepsis: A Review

Plasma Proteome Signature of Sepsis: a Functionally Connected Protein Network

Modulation of Metabolomic Profile in Sepsis According to the State of Immune Activation

Integrative analysis of metabolomics and proteomics reveals amino acid metabolism disorder in sepsis